Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome)

Schopfer K, Miebach E, Beck M, Pitz S. Lysosomal storage diseases: update and new therapeutic options. Klin Monbl Augenheilkd. 2011;228(2):144–60. https://doi.org/10.1055/s-0028-1109958.

Article  CAS  PubMed  Google Scholar 

Parkinson-Lawrence EJ, Shandala T, Prodoehl M, et al. Lysosomal storage disease: revealing lysosomal function and physiology. Physiology. 2010;25:102–15. https://doi.org/10.1152/physiol.00041.2009.

Article  CAS  PubMed  Google Scholar 

Desnick RJ, Schuchman EH. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu Rev Genomics Hum Genet. 2012;13:307–35. https://doi.org/10.1146/annurev-genom-090711-163739.

Article  CAS  PubMed  Google Scholar 

Scarpa M, Bellettato CM, Lampe C, Begley DJ. Neuronopathic lysosomal storage disorders: approaches to treat the central nervous system. Best Pract Res Clin Endocrinol Metab. 2015;29:159–71. https://doi.org/10.1016/j.beem.2014.12.001.

Article  CAS  PubMed  Google Scholar 

Tokic V, Barisic I, Huzjak N, et al. Enzyme replacement therapy in two patients with an advanced severe (Hurler) phenotype of mucopolysaccharidosis I. Eur J Pediatr. 2007;166:727–32. https://doi.org/10.1007/s00431-006-0316-8.

Article  PubMed  Google Scholar 

Lim-Melia ER, Kronn DF. Current enzyme replacement therapy for the treatment of lysosomal storage diseases. Pediatr Ann. 2009;38(8):448–55. https://doi.org/10.3928/00904481-20090723-09.

Article  PubMed  Google Scholar 

Beck M. Therapy for lysosomal storage disorders. IUBMB Life. 2010;62(1):33–40. https://doi.org/10.1002/iub.284.

Article  CAS  PubMed  Google Scholar 

Al Sawaf S, Mayatepek E, Hoffmann B. Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed. J Inherit Metab Dis. 2008;31:473–80. https://doi.org/10.1007/s10545-008-0878-x.

Article  CAS  PubMed  Google Scholar 

Muenzer J, Beck M, Eng CM, et al. Multidisciplinary management of Hunter syndrome. Pediatrics. 2009;124(6):e1228–39. https://doi.org/10.1542/peds.2008-0999.

Article  PubMed  Google Scholar 

Noh H, Lee JI. Current and potential therapeutic strategies for mucopolysaccharidoses. J Clin Pharm Ther. 2014;39:215–24. https://doi.org/10.1111/jcpt.12136.

Article  CAS  PubMed  Google Scholar 

Patel MM, Patel BM. Crossing the blood–brain barrier: recent advances in drug delivery to the brain. CNS Drugs. 2017;31(2):109–33. https://doi.org/10.1007/s40263-016-0405-9.

Article  CAS  PubMed  Google Scholar 

Giugliani R, Dalla Corte A, Poswar F, et al. Intrathecal/intracerebroventricular enzyme replacement therapy for the mucopolysaccharidoses: efficacy, safety, and prospects. Expert Opin Orphan Drugs. 2018;6(7):403–11. https://doi.org/10.1080/21678707.2018.1487838.

Article  CAS  Google Scholar 

Sato Y, Okuyama T. Novel enzyme replacement therapies for neuropathic mucopolysaccharidoses. Int J Mol Sci. 2020;21(2):400. https://doi.org/10.3390/ijms21020400.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pardridge WM. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconjug Chem. 2008;19(7):1327–38. https://doi.org/10.1021/bc800148t.

Article  CAS  PubMed  Google Scholar 

Lu JZ, Hui EK-W, Boado RJ, Pardridge WM. Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase. Bioconjug Chem. 2010;21:151–6. https://doi.org/10.1021/bc900382q.

Article  CAS  PubMed  Google Scholar 

Pardridge WM. Blood-brain barrier biology and methodology. J Neurovirol. 1999;5(6):556–69. https://doi.org/10.3109/13550289909021285.

Article  CAS  PubMed  Google Scholar 

Pardridge WM. Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody. Expert Opin Drug Deliv. 2015;12(2):207–22. https://doi.org/10.1517/17425247.2014.952627.

Article  CAS  PubMed  Google Scholar 

Boado RJ, Zhang Y, Zhang Y, Pardridge WM. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng. 2007;96(2):381–91. https://doi.org/10.1002/bit.21120.

Article  CAS  PubMed  Google Scholar 

Sonoda H, Morimoto H, Yoden E, et al. A blood–brain–barrier-penetrating anti-human transferrin receptor antibody fusion protein for neuronopathic mucopolysaccharidosis II. Mol Ther. 2018;26(5):1366–74. https://doi.org/10.1016/j.ymthe.2018.02.032.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morimoto H, Kida S, Yoden E, et al. Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice. Mol Ther. 2021;29(5):1853–61. https://doi.org/10.1016/j.ymthe.2021.01.027.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Okuyama T, Eto Y, Sakai N, et al. Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic mucopolysaccharidosis II: a phase 1/2 trial. Mol Ther. 2019;27:456–64. https://doi.org/10.1016/j.ymthe.2018.12.005.

Article  CAS  PubMed  Google Scholar 

Giugliani R, Martins AM, So S, et al. Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil. Mol Ther. 2021;29(7):2378–86. https://doi.org/10.1016/j.ymthe.2021.03.019.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Okuyama T, Eto Y, Sakai N, et al. A phase 2/3 trial of pabinafusp alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II. Mol Ther. 2021;29(2):671–9. https://doi.org/10.1016/j.ymthe.2020.09.039.

Article  CAS  PubMed  Google Scholar 

Denali Therapeutics. Denali Therapeutics announces new interim data from phase 1/2 study of DNL310 (ETV:IDS) in MPS II (Hunter syndrome) at SSIEM 2022. News release. August 31, 2022. Available from: https://www.globenewswire.com/news-release/2022/08/31/2507598/0/en/Denali-Therapeutics-Announces-New-Interim-Data-from-Phase-1-2-Study-of-DNL310-ETV-IDS-in-MPS-II-Hunter-Syndrome-at-SSIEM-2022.html. Accessed 31 Aug 2022.

Ullman JC, Arguello A, Getz JA, et al. Brain delivery and activity of a lysosomal enzyme using a blood–brain barrier transport vehicle in mice. Sci Transl Med. 2020;12(545): eaay1163. https://doi.org/10.1126/scitranslmed.aay1163.

Article  CAS  PubMed  Google Scholar 

Arguello A, Meisner R, Thomsen ER, et al. Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome. JCI Insight. 2021;6(19): e145445. https://doi.org/10.1172/jci.insight.145445.

Article  PubMed  PubMed Central  Google Scholar 

Boado RJ, Hui EKW, Lu JZ, Sumbria RK, Pardridge WM. Blood–brain barrier molecular Trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. Bioconjug Chem. 2013;24(10):1741–9. https://doi.org/10.1021/bc400319d.

Article  CAS  PubMed  Google Scholar 

ArmaGen Technologies. Pipeline-chart. Available from: http://armagen.com/our-pipeline/pipeline-chart. Accessed 10 Jan 2023.

Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82(1):70–7. https://doi.org/10.1016/0003-9861(59)90090-6.

Article  CAS  PubMed  Google Scholar 

Simpson RJ. Proteins and proteomics: a laboratory manual. Cold Spring Harbor: CSHL Press; 2003. (ISBN 0 87969 554).

Google Scholar 

Agilent. N-glycan preparation with InstantAB Kit user manual. Available from: https://www.agilent.com/cs/library/usermanuals/public/TDW-GP96NG-LB%20GlykoPrep%20Rapid%20N-Glycan%20Preparation%20with%20InstantAB%20090414AL.pdf. Accessed 1 Sep 2021.

Voznyi YV, Keulemans JLM, van Diggelen OP. A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease). J Inhert Metab Dis. 2001;24(6):675–80. https://doi.org/10.1023/a:1012763026526.

Article  CAS  Google Scholar 

Tolun AA, Graham C, Shi Q, et al. A novel fluorometric enzyme analysis method for Hunter syndrome using dried blood spots. Mol Genet Metab. 2012;105(3):519–21. https://doi.org/10.1016/j.ymgme.2011.12.011.

Article  CAS  PubMed  Google Scholar 

Kim C, Seo J, Chung Y, et al. Comparative study of idursulfase beta and idursulfase in vitro and in vivo. J Hum Genet. 2017;62(2):167–74. https://doi.org/10.1038/jhg.2016.133.

Article  CAS  PubMed  Google Scholar 

Chung YK, Sohn YB, Sohn JM, et al. A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of hunter syndrome. Glycoconj J. 2014;31(4):309–15. https://doi.org/10.1007/s10719-014-9523-0.

Article  CAS  PubMed  Google Scholar 

Dierks T, Schmidt B, von Figura K. Conversion of cysteine to formylglycine: a protein modification in the endoplasmic reticulum. Proc Natl Acad Sci USA. 1997;94(22):11963–8. https://doi.org/10.1073/pnas.94.22.11963.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Millat G, Froissart R, Maire I, Bozon D. Characterization of iduronate sulphatase mutants affecting N-glycosylation sites and the cysteine-84 residue. Biochem J. 1997;326:243–7. https://doi.org/10.1042/bj3260243.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ, Kimura A. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab. 2007;90(3):329–37. https://doi.org/10.1016/j.ymgme.2006.09.001.

Article  CAS  PubMe

留言 (0)

沒有登入
gif